Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialW. Timothy Garvey, Anuj Bhargava, Naveed Sattar et al.|The Lancet|2023Cited by 676
Role of TLR4/NADPH oxidase/ROS-activated p38 MAPK in VCAM-1 expression induced by lipopolysaccharide in human renal mesangial cellsI‐Te Lee, Chuen‐Mao Yang|Cell Communication and Signaling|2012Cited by 108